Trough Forced expiratory volume in one second (FEV1) response was defined as the change from baseline in trough FEV1. Trough FEV1 was defined as the mean of the two FEV1 measurements recorded at the pre-dose measurements (40 and 15 minutes before the drug administration) at the end of the dosing interval (24 hours post previous drug administration from the Respimat® Inhaler). Baseline FEV1 was pre-treatment FEV1 values measured at Day 1 of treatment period (baseline) prior to administration of the first dose of study medication, which was the mean of the measurements recorded from the pulmonary function tests taken at 40 and 15 minutes prior to drug administration at Day 1 of treatment period.

The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.

Trough Forced expiratory volume in one second (FEV1) response was defined as the change from baseline in trough FEV1. Trough FEV1 was defined as the mean of the two FEV1 measurements recorded at the pre-dose measurements (40 and 15 minutes before the drug administration) at the end of the dosing interval (24 hours post previous drug administration from the Respimat® Inhaler). Baseline FEV1 was pre-treatment FEV1 values measured at Day 1 of treatment period (baseline) prior to administration of the first dose of study medication, which was the mean of the measurements recorded from the pulmonary function tests taken at 40 and 15 minutes prior to drug administration at Day 1 of treatment period.

The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.

Trough forced vital capacity (FVC) response was defined as the change from baseline in trough FVC. Trough FVC was defined as the mean of the two FVC measurements recorded at the pre-dose measurements (40 and 15 minutes before drug administration) at the end of the dosing interval (24 hours post previous drug administration from the Respimat® Inhaler), which were obtained through spirometry at the same time points as for forced expiratory volume in one second. Baseline FVC was the mean of the two measurements of FVC taken at 40 and 15 minutes before drug administration at Day 1 of treatment period.

The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.

Forced expiratory volume in one second (FEV1) area under the curve from 0 to 3 hours (AUC0-3h) response after 0, 4, 12 and 24 weeks are reported. The FEV1 AUC0-3h response is the area under the curve from 0 to 3 hours post drug administration for change from baseline values of FEV1. The area under the curve (AUC) is calculated as the area under the curve from 0 to 3 hours at weeks 0, 4, 12 and 24 using the trapezoidal rule and using planned time, divided by the full duration (3 hours) to report in litres. The mean of the pre-dose values (at 40 minutes and 15 minutes before dosing) are used with a time value of zero for calculating the AUC values starting at zero. The baseline FEV1 is the mean of the two measurements taken at 40 and 15 minutes before drug administration at Day 1 of treatment period.

The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.

Forced vital capacity (FVC) area under the curve from 0 to 3 hours (AUC0-3h) response after 0, 4, 12 and 24 weeks are reported. The FVC AUC0-3h response is the area under the curve from 0 to 3 hours post drug administration for change from baseline values of FVC. The area under the curve (AUC) is calculated as the area under the curve from 0 to 3 hours at weeks 0, 4, 12 and 24 using the trapezoidal rule and using planned time, divided by the full duration (3 hours) to report in litres. The mean of the pre-dose values (at 40 minutes and 15 minutes before dosing) are used with a time value of zero for calculating the AUC values starting at zero. The baseline FVC is the mean of the two measurements taken at 40 and 15 minutes before drug administration at Day 1 of treatment period.

The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.

Forced expiratory volume in one second (FEV1) peak response after 0, 4, 12, and 24 weeks were reported. Peak FEV1 response was the maximum change from baseline for the post-dose measurements of FEV1. Baseline FEV1 is the mean of the two measurements taken at 40 and 15 minutes before drug administration.

The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.

Forced Vital Capacity (FVC) peak response after 0, 4, 12, and 24 weeks were reported. Peak FVC response was the maximum change from baseline for the post-dose measurements of FVC. Baseline FVC is the mean of the two measurements taken at 40 and 15 minutes before drug administration.

The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.

Individual Forced expiratory volume in one second (FEV1) values measured at each time points at Week 0, 4, 12, and 24 were reported.

The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.

Individual Forced Vital Capacity (FVC) values measured at each time point at Week 0, 4, 12, and 24 were reported.

The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.

Trough Forced expiratory volume in one second (FEV1) response on Day 3 and 5 are reported, for which the FEV1 response is the change from baseline in trough FEV1. Trough FEV1 for respective day (Day 3 or Day 5)was defined as the mean of the two FEV1 measurements recorded at the pre-dose measurements (40 and 15 minutes before the drug administration) at the end of the dosing interval (24 hours post previous drug administration from the Respimat® Inhaler) at that day. Baseline FEV1 was pre-treatment FEV1 values measured at Day 1 of treatment period (baseline) prior to administration of the first dose of study medication, which was the mean of the measurements recorded from the pulmonary function tests taken at 40 and 15 minutes prior to drug administration at Day 1 of treatment period.

Sub-study set (SUB): This patient set includes all patients in the full analysis set that were enrolled in the sub-study (at selected sites only) and have acceptable non-missing forced expiratory volume in one second (FEV1) data from 2 additional visits on Day 3 and 5.

Forced expiratory volume in one second (FEV1) values at 3 minutes and 10 minutes following drug administration at Week 0, 4, 12, and 24 are reported.

Sub-study set (SUB): This patient set includes all patients in the full analysis set that were enrolled in the sub-study (at selected sites only) and have acceptable non-missing forced expiratory volume in one second (FEV1) data from 2 additional visits on Day 3 and 5.

Forced Vital Capacity (FVC) values at 3 minutes and 10 minutes following drug administration at Week 0, 4, 12, and 24 are reported.

Sub-study set (SUB): This patient set includes all patients in the full analysis set that were enrolled in the sub-study (at selected sites only) and have acceptable non-missing forced expiratory volume in one second (FEV1) data from 2 additional visits on Day 3 and 5.

The patient recorded twice daily peak flow measurements with an electronic peak flow meter throughout the entire evaluation period. Morning measurements were performed immediately upon arising after the patient had cleared out mucus, prior to administration of trial and/or rescue medication. The evening measurements were performed at bedtime. The weekly mean morning peak expiratory flow rate (PEFR) is reported.

The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.

The patient recorded twice daily peak flow measurements with an electronic peak flow meter throughout the entire evaluation period. Morning measurements were performed immediately upon arising after the patient had cleared out mucus, prior to administration of trial and/or rescue medication. The evening measurements were performed at bedtime. The weekly mean of evening peak expiratory flow rate (PEFR) is reported.

The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.

The patient recorded the number of occasions salbutamol (albuterol) Metered Dose Inhaler (MDI) was used each day and night during the entire evaluation period. The weekly mean number of occasions of rescue therapy used per day (PRN salbutamol [albuterol]) is reported.

The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.

Physicians make a global evaluation reflecting the physician's global opinion of the overall clinical condition of the patient as "poor" (score 1 or 2), "fair" (score 3 or 4), "good" (score 5 or 6), or "excellent" (score 7 or 8). These assessments are made prior to pulmonary function testing and are summarized on pulmonary function test days. This evaluation was based on the need for concomitant medication, number and severity of exacerbations since the last visit, severity of cough, ability to exercise, amount of wheezing, and other relevant clinical observations. The score ranges from 1 to 8 with higher score indicating better overall clinical condition.

The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.

The transitional dyspnea index (TDI) evaluates the patient's condition related to breathlessness. The TDI includes three domains: functional impairment, magnitude of task, and magnitude of effort. The TDI domain score of functional impairment is reported, which domain score ranges from -3 (major deterioration in the ability of working and doing activities due to shortness of breath; the worst score) to 3 (major improvement in the ability of working and doing activities; mild restriction on full activities due to the improvement of shortness of breath; the best score).

The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.

The transitional dyspnea index (TDI) evaluates the patient's condition related to breathlessness. The TDI includes three domains: functional impairment, magnitude of task, and magnitude of effort. The TDI domain score of magnitude of task is reported, which domain score ranges from -3 (major deterioration from baseline status; the worst score) to 3 (major improvement from baseline status; the best score).

The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.

The transitional dyspnea index (TDI) evaluates the patient's condition related to breathlessness. The TDI includes three domains: functional impairment, magnitude of task, and magnitude of effort. The TDI domain score of magnitude of effort is reported, which sub-score ranges from -3 (severe decrease in effort from baseline to avoid shortness of breath. Activities now take 50-100% longer to complete than required at baseline; the worst score) to 3 (Able to do things with much greater effort than previously with few pauses. Activities may be performed 50- 100% more rapidly than at baseline; the best score).

The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement.

The St. George's Respiratory Questionnaire (SGRQ) is a well-established, self-completed tool measuring health-related quality of life in patients with diseases of airways obstruction on three aspects of symptoms, activity, and impacts. The total SGRQ score is reported, which ranges from 0 (the best score) to 100 (the worst score) with smaller score value indicating less limitations due to breathlessness and better quality of life.

The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement. Only patients with non-missing outcomes are included in the analysis.

The 36-item-health Survey (SF-36) is a multi-purpose, short-form health survey with 36 questions evaluating patient's physical and mental health. Among the 36 questions, 1 is on the health comparing to 1 year ago and the remaining 35 questions are divided into 8 domains: Physical function (10 questions), role physical (4 questions), Bodily pain (2 questions), General physical health (5 questions), Vitality (4 questions), Social functioning (2 questions), role emotional (3 questions), and General mental health (5 questions). Each domain score is the weighted sum of the questions in the corresponding domain with the domain score ranging from 0 to 100. The higher the score value, the better the health condition.

The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement. Only patients with non-missing outcomes are included in the analysis.

The 36-item-health Survey (SF-36) is a multi-purpose, short-form health survey with 36 questions evaluating patient's physical and mental health. Among the 36 questions, 1 is on the health comparing to 1 year ago and the remaining 35 questions are divided into 8 domains: Physical function, role limitations physical, Bodily pain, General physical health, Vitality, Social functioning, role limitations emotional, and General mental health.

The domain score of physical function (based on 10 questions) is reported, which is the weighted sum of the questions in corresponding domain with the domain score ranging from 0 to 100. The higher the domain score, the better the physical function.

The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement. Only patients with non-missing outcomes are included in the analysis.

The 36-item-health Survey (SF-36) is a multi-purpose, short-form health survey with 36 questions evaluating patient's physical and mental health. Among the 36 questions, 1 is on the health comparing to 1 year ago and the remaining 35 questions are divided into 8 domains: Physical function, role limitations physical, Bodily pain, General physical health, Vitality, Social functioning, role limitations emotional, and General mental health.

The domain score of role limitations due to physical health problems (based on 4 questions) is reported, which is the weighted sum of the questions in the corresponding domain with the domain score ranging from 0 to 100. The higher the domain score, the less limitations in roles due to physical health problems.

The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement. Only patients with non-missing outcomes are included in the analysis.

The 36-item-health Survey (SF-36) is a multi-purpose, short-form health survey with 36 questions evaluating patient's physical and mental health. Among the 36 questions, 1 is on the health comparing to 1 year ago and the remaining 35 questions are divided into 8 domains: Physical function, role limitations physical, Bodily pain, General physical health, Vitality, Social functioning, role limitations emotional, and General mental health.

The domain score of bodily pain (based on 2 questions) is reported, which is the weighted sum of the questions in the corresponding domain with the domain score ranging from 0 to 100. The higher the domain score, the less severer the bodily pain.

The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement. Only patients with non-missing outcomes are included in the analysis.

The 36-item-health Survey (SF-36) is a multi-purpose, short-form health survey with 36 questions evaluating patient's physical and mental health. Among the 36 questions, 1 is on the health comparing to 1 year ago and the remaining 35 questions are divided into 8 domains: Physical function, role limitations physical, Bodily pain, General physical health, Vitality, Social functioning, role limitations emotional, and General mental health.

The domain score of general physical health (based on 5 questions) is reported, which is the weighted sum of the questions in the corresponding domain with the domain score ranging from 0 to 100. The higher the domain score, the better the physical health in general.

The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement. Only patients with non-missing outcomes are included in the analysis.

The 36-item-health Survey (SF-36) is a multi-purpose, short-form health survey with 36 questions evaluating patient's physical and mental health. Among the 36 questions, 1 is on the health comparing to 1 year ago and the remaining 35 questions are divided into 8 domains: Physical function, role limitations physical, Bodily pain, General physical health, Vitality, Social functioning, role limitations emotional, and General mental health.

The domain score of vitality (based on 4 questions) is reported, which is the weighted sum of the questions in the corresponding domain with the domain score ranging from 0 to 100. The higher the domain score, the more vitality and less fatigue one has.

The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement. Only patients with non-missing outcomes are included in the analysis.

The 36-item-health Survey (SF-36) is a multi-purpose, short-form health survey with 36 questions evaluating patient's physical and mental health. Among the 36 questions, 1 is on the health comparing to 1 year ago and the remaining 35 questions are divided into 8 domains: Physical function, role limitations physical, Bodily pain, General physical health, Vitality, Social functioning, role limitations emotional, and General mental health.

The domain score of Social functioning (based on 2 questions) is reported, which is the weighted sum of the questions in the corresponding domain with the domain score ranging from 0 to 100. The higher the domain score, the better the social functioning.

The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement. Only patients with non-missing outcomes are included in the analysis.

The 36-item-health Survey (SF-36) is a multi-purpose, short-form health survey with 36 questions evaluating patient's physical and mental health. Among the 36 questions, 1 is on the health comparing to 1 year ago and the remaining 35 questions are divided into 8 domains: Physical function, role limitations physical, Bodily pain, General physical health, Vitality, Social functioning, role limitations emotional, and General mental health.

The domain score of role emotional (based on 4 questions) is reported, which is the weighted sum of the questions in the corresponding domain with the domain score ranging from 0 to 100. The higher the domain score, the less limitation in roles due to emotional problems.

The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement. Only patients with non-missing outcomes are included in the analysis.

The 36-item-health Survey (SF-36) is a multi-purpose, short-form health survey with 36 questions evaluating patient's physical and mental health. Among the 36 questions, 1 is on the health comparing to 1 year ago and the remaining 35 questions are divided into 8 domains: Physical function, role limitations physical, Bodily pain, General physical health, Vitality, Social functioning, role limitations emotional, and General mental health.

The domain score of general mental health (based on 5 questions) is reported, which is the weighted sum of the questions in the corresponding domain with the domain score ranging from 0 to 100. The higher the domain score, the better the mental health in general.

The full analysis set (FAS) was defined as all patients in treated set with at least baseline Forced expiratory volume in one second (FEV1) data and at least one acceptable post-treatment trough FEV1 measurement. Only patients with non-missing outcomes are included in the analysis.

Number of patients with at least one Chronic Obstructive Pulmonary Disease (COPD) exacerbation is reported. Incidence rate of Chronic Obstructive Pulmonary Disease (COPD) exacerbation is reported. A Chronic Obstructive Pulmonary Disease (COPD) exacerbation is defined as "a complex of lower respiratory events / symptoms (increase or new onset) related to the underlying COPD, with a duration of three days or more, requiring a change in treatment", where a "complex of lower respiratory events / symptoms" means at least two of the following: Shortness of breath, Sputum production (volume), Occurrence of purulent sputum, Cough, Wheezing, Chest tightness.

Treated Set (TS): The treated set was defined as all patients who were randomized and who took at least one dose of trial medication.

Incidence rate of Chronic Obstructive Pulmonary Disease (COPD) exacerbation is reported. A Chronic Obstructive Pulmonary Disease (COPD) exacerbation is defined as "a complex of lower respiratory events / symptoms (increase or new onset) related to the underlying COPD, with a duration of three days or more, requiring a change in treatment", where a "complex of lower respiratory events / symptoms" means at least two of the following: Shortness of breath, Sputum production (volume), Occurrence of purulent sputum, Cough, Wheezing, Chest tightness.

Treated Set (TS): The treated set was defined as all patients who were randomized and who took at least one dose of trial medication.